OncoMatch/Clinical Trials/NCT07067268
Tislelizumab Combined With Capecitabine for Nasopharyngeal Carcinoma With Residual EBV DNA After Radiotherapy
Is NCT07067268 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Adjuvant therapy for nasopharyngeal cancinoma (npc).
Treatment: Adjuvant therapy — This study aims to explore the efficacy and safety of tislelizumab combined with capecitabine in nasopharyngeal carcinoma patients with residual plasma EBV DNA after radiotherapy.
Check if I qualifyExtracted eligibility criteria
Cancer type
Head and Neck Squamous Cell Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: radiation therapy — definitive
Lab requirements
Blood counts
Hemoglobin ≥90 g/L; ANC ≥1.0×10⁹/L; Platelet count ≥80×10⁹/L
Kidney function
Serum creatinine ≤ULN, and creatinine clearance rate ≥50 mL/min (Cockcroft-Gault formula)
Liver function
Total bilirubin <1.5× ULN; ALT and AST <2.5× ULN
Cardiac function
Normal myocardial enzymes and thyroid function; Normal cardiac function assessed by echocardiography
Adequate organ function meeting the following criteria: Hematological: a. Hemoglobin (HB) ≥90 g/L; b. Absolute neutrophil count (ANC) ≥1.0×10⁹/L; c. Platelet count (PLT) ≥80×10⁹/L; Biochemical: a. Total bilirubin (BIL) <1.5× ULN; b. ALT and AST <2.5×ULN; c. Serum creatinine (Cr) ≤ULN, and creatinine clearance rate ≥50 mL/min (calculated by Cockcroft-Gault formula); d. Normal myocardial enzymes and thyroid function; e. Normal cardiac function assessed by echocardiography.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify